|
|
J Clin Invest. 1986 November; 78(5): 1410–1414. doi: 10.1172/JCI112729. | PMCID: PMC423848 |
In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia. G L Vega and S M Grundy Abstract The causes of primary moderate hypercholesterolemia are not understood, but some patients have reduced fractional clearance rates (FCRs) for low density lipoproteins (LDL). This could be due to either decreased activity of LDL receptors or to a defect in structure (or composition) of LDL that reduces its affinity for receptors. To distinguish between these causes, simultaneous turnover rates of autologous and normal homologous LDL were determined in 15 patients with primary moderate hypercholesterolemia. In 10, turnover rates of both types of LDL were indistinguishable, which indicated that autologous LDL was cleared as efficiently as normal homologous LDL. In five others, FCRs for autologous LDL were significantly lower than for homologous LDL. Two of the latter five were treated with mevinolin, and although FCRs for both types of LDL rose during treatment, differences in FCRs between the two types of LDL persisted. In these five patients, autologous LDL appeared to be a poor ligand for LDL receptors. Full text Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (842K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References. These references are in PubMed. This may not be the complete list of references from this article. - Grundy SM, Vega GL. Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia. J Lipid Res. 1985 Dec;26(12):1464–1475. [PubMed]
- Heiss G, Tamir I, Davis CE, Tyroler HA, Rifkand BM, Schonfeld G, Jacobs D, Frantz ID., Jr Lipoprotein-cholesterol distributions in selected North American populations: the lipid research clinics program prevalence study. Circulation. 1980 Feb;61(2):302–315. [PubMed]
- Nora JJ, Lortscher RM, Spangler RD, Bilheimer DW. Familial hypercholesterolemia with "normal" cholesterol in obligate heterozygotes. Am J Med Genet. 1985 Nov;22(3):585–591. [PubMed]
- McDougal JS, Cort SP, Kennedy MS, Cabridilla CD, Feorino PM, Francis DP, Hicks D, Kalyanaraman VS, Martin LS. Immunoassay for the detection and quantitation of infectious human retrovirus, lymphadenopathy-associated virus (LAV). J Immunol Methods. 1985 Jan 21;76(1):171–183. [PubMed]
- MATTHEWS CM. The theory of tracer experiments with 131I-labelled plasma proteins. Phys Med Biol. 1957 Jul;2(1):36–53. [PubMed]
- Vega GL, Groszek E, Wolf R, Grundy SM. Influence of polyunsaturated fats on composition of plasma lipoproteins and apolipoproteins. J Lipid Res. 1982 Aug;23(6):811–822. [PubMed]
- Weisgraber KH, Rall SC, Jr, Mahley RW. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem. 1981 Sep 10;256(17):9077–9083. [PubMed]
- Simons LA, Reichl D, Myant NB, Mancini M. The metabolism of the apoprotein of plasma low density lipoprotein in familial hyperbetalipoproteinaemia in the homozygous form. Atherosclerosis. 1975 Mar–Apr;21(2):283–298. [PubMed]
- Kesaniemi YA, Grundy SM. Increased low density lipoprotein production associated with obesity. Arteriosclerosis. 1983 Mar–Apr;3(2):170–177. [PubMed]
- Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci U S A. 1983 Jul;80(13):4124–4128. [PubMed]
- Grundy SM, Vega GL, Bilheimer DW. Kinetic mechanisms determining variability in low density lipoprotein levels and rise with age. Arteriosclerosis. 1985 Nov–Dec;5(6):623–630. [PubMed]
- Priestley L, Knott T, Wallis S, Powell L, Pease R, Simon A, Scott J. RFLP for the human apolipoprotein B gene: I;BamHI. Nucleic Acids Res. 1985 Sep 25;13(18):6789. [PubMed]
- Chan L, VanTuinen P, Ledbetter DH, Daiger SP, Gotto AM, Jr, Chen SH. The human apolipoprotein B-100 gene: a highly polymorphic gene that maps to the short arm of chromosome 2. Biochem Biophys Res Commun. 1985 Nov 27;133(1):248–255. [PubMed]
- Knott TJ, Rall SC, Jr, Innerarity TL, Jacobson SF, Urdea MS, Levy-Wilson B, Powell LM, Pease RJ, Eddy R, Nakai H, et al. Human apolipoprotein B: structure of carboxyl-terminal domains, sites of gene expression, and chromosomal localization. Science. 1985 Oct 4;230(4721):37–43. [PubMed]
- Deeb SS, Motulsky AG, Albers JJ. A partial cDNA clone for human apolipoprotein B. Proc Natl Acad Sci U S A. 1985 Aug;82(15):4983–4986. [PubMed]
- Innerarity TL, Mahley RW. Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins. Biochemistry. 1978 Apr 18;17(8):1440–1447. [PubMed]
|
This article has been